Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Dec 14;5(12):e14322.
doi: 10.1371/journal.pone.0014322.

Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount

Affiliations

Physician attitudes towards pharmacological cognitive enhancement: safety concerns are paramount

Opeyemi C Banjo et al. PLoS One. .

Abstract

The ethical dimensions of pharmacological cognitive enhancement have been widely discussed in academic circles and the popular media, but missing from the conversation have been the perspectives of physicians - key decision makers in the adoption of new technologies into medical practice. We queried primary care physicians in major urban centers in Canada and the United States with the aim of understanding their attitudes towards cognitive enhancement. Our primary hypothesis was that physicians would be more comfortable prescribing cognitive enhancers to older patients than to young adults. Physicians were presented with a hypothetical pharmaceutical cognitive enhancer that had been approved by the regulatory authorities for use in healthy adults, and was characterized as being safe, effective, and without significant adverse side effects. Respondents overwhelmingly reported increasing comfort with prescribing cognitive enhancers as the patient age increased from 25 to 65. When asked about their comfort with prescribing extant drugs that might be considered enhancements (sildenafil, modafinil, and methylphenidate) or our hypothetical cognitive enhancer to a normal, healthy 40 year old, physicians were more comfortable prescribing sildenafil than any of the other three agents. When queried as to the reasons they answered as they did, the most prominent concerns physicians expressed were issues of safety that were not offset by the benefit afforded the individual, even in the face of explicit safety claims. Moreover, many physicians indicated that they viewed safety claims with considerable skepticism. It has become routine for safety to be raised and summarily dismissed as an issue in the debate over pharmacological cognitive enhancement; the observation that physicians were so skeptical in the face of explicit safety claims suggests that such a conclusion may be premature. Thus, physician attitudes suggest that greater weight be placed upon the balance between safety and benefit in consideration of pharmacological cognitive enhancement.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Physicians' Comfort Rating with Prescribing Cognitive Enhancers to Patients of Differing Ages.
(A) Mean physician comfort rating with prescribing the hypothetical cognitive enhancer to patients of differing ages. Physicians reported increasing comfort with prescribing cognitive enhancers as the patient's age increased from 25 to 65 (P<0.001). (B) Frequency of occurrence of each response on a 7-point Likert scale, with anchors at 1 (less comfortable) and 7(more comfortable).
Figure 2
Figure 2. Physicians' Comfort Rating with Prescribing Sildenafil, Methylphenidate, Modafinil, and a Hypothetical Cognitive Enhancer.
Physicians reported being significantly more comfortable prescribing sildenafil compared to the other 3 drugs (P<0.001); while methylphenidate was rated significantly lower (P<0.01) when compared with sildenafil and the cognitive enhancer, but not modafinil.

Similar articles

Cited by

References

    1. Bostrom N. In defense of posthuman dignity. Bioethics. 2005;3:202–214. - PubMed
    1. Fukuyama F. New York: Farrar, Straus and Giroux ; 2002. Our posthuman future: consequences of the biotechnology revolution.256
    1. President's Council on Bioethics. New York: Dana Press ; 2003. Beyond therapy: biotechnology and the pursuit of happiness.400
    1. Hunt E. The role of intelligence in modern society. American Scientist. 1995;83:356–367.
    1. Brooks D. The cognitive age. 2008. The New York Times, 2008 2 May. Available: http://www.nytimes.com/2008/05/02/opinion/02brooks.html. Accessed 2010 4 June.

Publication types

MeSH terms